SG11201500872SA - Novel pyrrolopyrimidine compounds as inhibitors of protein kinases - Google Patents
Novel pyrrolopyrimidine compounds as inhibitors of protein kinasesInfo
- Publication number
- SG11201500872SA SG11201500872SA SG11201500872SA SG11201500872SA SG11201500872SA SG 11201500872S A SG11201500872S A SG 11201500872SA SG 11201500872S A SG11201500872S A SG 11201500872SA SG 11201500872S A SG11201500872S A SG 11201500872SA SG 11201500872S A SG11201500872S A SG 11201500872SA
- Authority
- SG
- Singapore
- Prior art keywords
- inhibitors
- protein kinases
- pyrrolopyrimidine compounds
- novel pyrrolopyrimidine
- novel
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261680231P | 2012-08-06 | 2012-08-06 | |
| US13/843,554 US9034885B2 (en) | 2012-01-13 | 2013-03-15 | EGFR modulators and uses thereof |
| US201361814147P | 2013-04-19 | 2013-04-19 | |
| US13/917,514 US8685988B2 (en) | 2012-08-06 | 2013-06-13 | EGFR modulators and uses thereof |
| PCT/US2013/050163 WO2014025486A1 (en) | 2012-08-06 | 2013-07-11 | Novel pyrrolopyrimidine compounds as inhibitors of protein kinases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201500872SA true SG11201500872SA (en) | 2015-03-30 |
Family
ID=50068479
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201500872SA SG11201500872SA (en) | 2012-08-06 | 2013-07-11 | Novel pyrrolopyrimidine compounds as inhibitors of protein kinases |
Country Status (22)
| Country | Link |
|---|---|
| EP (2) | EP2880035B9 (ja) |
| JP (2) | JP6215938B2 (ja) |
| KR (1) | KR102181365B1 (ja) |
| CN (2) | CN107266453B (ja) |
| AU (1) | AU2013300106B2 (ja) |
| BR (1) | BR112015002709B1 (ja) |
| CA (1) | CA2881275C (ja) |
| CY (1) | CY1120844T1 (ja) |
| DK (1) | DK2880035T3 (ja) |
| ES (2) | ES2618007T3 (ja) |
| HK (1) | HK1210471A1 (ja) |
| HR (1) | HRP20170311T1 (ja) |
| HU (1) | HUE031955T2 (ja) |
| IN (1) | IN2015DN00914A (ja) |
| LT (1) | LT2880035T (ja) |
| MX (1) | MX361992B (ja) |
| NZ (1) | NZ629807A (ja) |
| PT (1) | PT2880035T (ja) |
| RU (2) | RU2018104702A (ja) |
| SG (1) | SG11201500872SA (ja) |
| WO (1) | WO2014025486A1 (ja) |
| ZA (2) | ZA201500762B (ja) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013013188A1 (en) | 2011-07-21 | 2013-01-24 | Tolero Pharmaceuticals, Inc. | Heterocyclic protein kinase inhibitors |
| US9464089B2 (en) | 2012-01-13 | 2016-10-11 | Acea Biosciences Inc. | Heterocyclic compounds and uses thereof |
| EP2802568A1 (en) | 2012-01-13 | 2014-11-19 | Acea Biosciences, Inc. | Heterocyclic compounds and uses as anticancer agents. |
| US9034885B2 (en) | 2012-01-13 | 2015-05-19 | Acea Biosciences Inc. | EGFR modulators and uses thereof |
| EP2945636B1 (en) * | 2013-01-16 | 2017-06-28 | Signal Pharmaceuticals, LLC | Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith |
| WO2014151871A2 (en) * | 2013-03-14 | 2014-09-25 | Tolero Pharmaceuticals, Inc. | Jak2 and alk2 inhibitors and methods for their use |
| NZ715687A (en) * | 2013-07-11 | 2019-04-26 | Acea Biosciences Inc | Pyrimidine derivatives as kinase inhibitors |
| WO2015127234A1 (en) * | 2014-02-20 | 2015-08-27 | Board Of Regents, The University Of Texas System | Use of ibrutinib to treat egfr mutant cancer |
| KR20170024120A (ko) | 2014-07-14 | 2017-03-06 | 시그날 파마소티칼 엘엘씨 | 치환된 피롤로피리미딘 화합물을 사용한 암의 치료방법, 이의 조성물 |
| NZ629796A (en) | 2014-07-14 | 2015-12-24 | Signal Pharm Llc | Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use |
| WO2016130920A2 (en) | 2015-02-13 | 2016-08-18 | Dana-Farber Cancer Institute, Inc. | Lrrk2 inhibitors and methods of making and using the same |
| JP2018104290A (ja) * | 2015-04-28 | 2018-07-05 | アステラス製薬株式会社 | ピラジンカルボキサミド化合物を有効成分とする医薬組成物 |
| EP3312179B1 (en) * | 2015-04-29 | 2019-07-10 | Nanjing Sanhome Pharmaceutical Co., Ltd. | Fused-ring or tricyclic aryl pyrimidine compound used as kinase inhibitor |
| WO2017011720A1 (en) * | 2015-07-16 | 2017-01-19 | Signal Pharmaceuticals, Llc | Solod forms 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d] oxazol-6-yl)17h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use |
| WO2017059702A1 (en) | 2015-10-09 | 2017-04-13 | Acea Biosciences, Inc | Pharmaceutical salts, physical forms, and compositions of pyrrolopyrimidine kinase inhibitors, and methods of making same |
| CN105646496B (zh) * | 2016-01-20 | 2018-07-20 | 华侨大学 | 一种7H-吡咯并[2,3-d]嘧啶衍生物、其合成方法及应用 |
| CN107540661A (zh) * | 2016-06-24 | 2018-01-05 | 正大天晴药业集团股份有限公司 | 作为egfr抑制剂的苯胺嘧啶化合物的结晶 |
| CN107663208B (zh) * | 2016-07-27 | 2021-10-15 | 南京圣和药业股份有限公司 | 一种新型egfr激酶抑制剂的药用盐及其制备方法与用途 |
| CN107663207B (zh) * | 2016-07-27 | 2021-07-30 | 南京圣和药业股份有限公司 | 一种egfr激酶抑制剂的甲磺酸盐结晶及制备方法 |
| CN107955019B (zh) * | 2016-10-17 | 2021-09-14 | 广东众生药业股份有限公司 | 一种egfr抑制剂的盐型、晶型及其制备方法 |
| CN106749266B (zh) * | 2016-11-14 | 2019-01-22 | 山东大学 | 吡咯并[2,3-d]嘧啶类化合物的高效制备方法 |
| CN108299419B (zh) * | 2017-01-11 | 2022-04-26 | 南京圣和药业股份有限公司 | 一种新型egfr激酶抑制剂的几种新晶型及其制备方法 |
| US11608334B2 (en) | 2017-02-08 | 2023-03-21 | The National Institutes of Pharmaceutical R&D Co., Ltd. | Pyrrolo-aromatic heterocyclic compound, preparation method therefor, and medical use thereof |
| US11498922B2 (en) | 2017-04-07 | 2022-11-15 | ACEA Therapeutics, Inc. | Pharmaceutical composition comprising N-(3-((2-((3-fluoro-4-(4-methylpiperazin-1-yl phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)phenylacrylamide |
| CN109422751B (zh) * | 2017-09-03 | 2022-04-22 | 上海美志医药科技有限公司 | 一类具有降解酪氨酸蛋白激酶jak3活性的化合物 |
| US11709155B2 (en) | 2017-09-18 | 2023-07-25 | Waters Technologies Corporation | Use of vapor deposition coated flow paths for improved chromatography of metal interacting analytes |
| US11709156B2 (en) | 2017-09-18 | 2023-07-25 | Waters Technologies Corporation | Use of vapor deposition coated flow paths for improved analytical analysis |
| KR102577241B1 (ko) | 2017-12-28 | 2023-09-11 | 주식회사 대웅제약 | 카이네이즈 저해제로서의 아미노-플루오로피페리딘 유도체 |
| KR102577242B1 (ko) * | 2017-12-28 | 2023-09-11 | 주식회사 대웅제약 | 카이네이즈 저해제로서의 아미노-메틸피페리딘 유도체 |
| KR102318929B1 (ko) * | 2017-12-28 | 2021-10-28 | 주식회사 대웅제약 | 카이네이즈 저해제로서의 옥시-플루오로피페리딘 유도체 |
| AU2019247498A1 (en) | 2018-04-05 | 2020-11-26 | Sumitomo Pharma Oncology, Inc. | AXL kinase inhibitors and use of the same |
| JP2021521170A (ja) | 2018-04-13 | 2021-08-26 | スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド | 骨髄増殖性新生物およびがんに関連する線維症の処置のためのｐｉｍキナーゼ阻害剤 |
| CN108530450B (zh) * | 2018-05-03 | 2021-03-30 | 赖建智 | 具有egfr抑制活性的化合物、制备方法及其在疾病治疗中的应用 |
| KR20210038906A (ko) | 2018-07-26 | 2021-04-08 | 스미토모 다이니폰 파마 온콜로지, 인크. | 비정상적 acvr1 발현과 연관된 질환을 치료하는 방법 및 그에 사용하기 위한 acvr1 억제제 |
| EP3613738A1 (en) * | 2018-08-23 | 2020-02-26 | Lead Discovery Center GmbH | 4-substituted pyrrolo[2,3-b]pyridine as erbb modulators useful for treating cancer |
| MX2021009371A (es) | 2019-02-12 | 2021-09-10 | Sumitomo Pharma Oncology Inc | Formulaciones que comprenden inhibidores de proteina cinasa heterociclicos. |
| CN111747931A (zh) * | 2019-03-29 | 2020-10-09 | 深圳福沃药业有限公司 | 用于治疗癌症的氮杂芳环酰胺衍生物 |
| CN110407840A (zh) * | 2019-08-15 | 2019-11-05 | 重庆化工职业学院 | 一种艾维替尼的制备方法 |
| CN117551103A (zh) * | 2019-11-13 | 2024-02-13 | 浙江龙传生物医药科技有限公司 | 作为btk抑制剂的吡咯并嘧啶类化合物及其应用 |
| US11918936B2 (en) | 2020-01-17 | 2024-03-05 | Waters Technologies Corporation | Performance and dynamic range for oligonucleotide bioanalysis through reduction of non specific binding |
| WO2021147952A1 (zh) * | 2020-01-21 | 2021-07-29 | 江苏先声药业有限公司 | 嘧啶并吡咯类化合物 |
| CN111848631B (zh) * | 2020-08-28 | 2022-04-19 | 四川大学华西医院 | 一种靶向EGFR突变的吡咯并[2,3-d]嘧啶衍生物及其制备方法和用途 |
| US20240100172A1 (en) | 2020-12-21 | 2024-03-28 | Hangzhou Jijing Pharmaceutical Technology Limited | Methods and compounds for targeted autophagy |
| CN114957248B (zh) * | 2022-05-09 | 2023-12-29 | 南开大学 | 一种吡咯并嘧啶化合物及其制备方法、药物组合物和应用 |
| CN115611989B (zh) * | 2022-10-09 | 2023-08-01 | 武汉理工大学 | 机械活化淀粉衍生物抑制剂的优化制备方法及应用 |
| WO2024092047A1 (en) | 2022-10-26 | 2024-05-02 | Sorrento Therapeutics, Inc. | Administration of pyrrolopyrimidine-based kinase inhibitors for treatment of psoriasis |
| WO2024097653A1 (en) | 2022-10-31 | 2024-05-10 | Sumitomo Pharma America, Inc. | Pim1 inhibitor for treating myeloproliferative neoplasms |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5563905A (en) | 1992-09-24 | 1996-10-08 | Hughes Aircraft Company | Network communication system having time-sliced protocol |
| US7732127B2 (en) | 2002-12-20 | 2010-06-08 | Acea Biosciences, Inc. | Dynamic monitoring of cell adhesion and spreading using the RT-CES system |
| US7192752B2 (en) | 2002-12-20 | 2007-03-20 | Acea Biosciences | Real time electronic cell sensing systems and applications for cell-based assays |
| AU2003267998A1 (en) | 2002-07-20 | 2004-02-09 | Acea Biosciences, Inc. | Impedance based devices and methods for use in assays |
| US7470533B2 (en) | 2002-12-20 | 2008-12-30 | Acea Biosciences | Impedance based devices and methods for use in assays |
| US7560269B2 (en) | 2002-12-20 | 2009-07-14 | Acea Biosciences, Inc. | Real time electronic cell sensing system and applications for cytotoxicity profiling and compound assays |
| US7468255B2 (en) | 2002-12-20 | 2008-12-23 | Acea Biosciences | Method for assaying for natural killer, cytotoxic T-lymphocyte and neutrophil-mediated killing of target cells using real-time microelectronic cell sensing technology |
| ES2381962T3 (es) * | 2005-09-21 | 2012-06-04 | 4Sc Ag | Nuevos sulfonilpirroles como inhibidores de las HDAC |
| KR101705158B1 (ko) * | 2009-05-05 | 2017-02-09 | 다나-파버 캔서 인스티튜트 인크. | Ｅｇｆｒ 억제제 및 질환 치료방법 |
| WO2011079231A1 (en) * | 2009-12-23 | 2011-06-30 | Gatekeeper Pharmaceutical, Inc. | Compounds that modulate egfr activity and methods for treating or preventing conditions therewith |
-
2013
- 2013-07-11 RU RU2018104702A patent/RU2018104702A/ru not_active Application Discontinuation
- 2013-07-11 CN CN201710229308.7A patent/CN107266453B/zh active Active
- 2013-07-11 HU HUE13745491A patent/HUE031955T2/en unknown
- 2013-07-11 BR BR112015002709-1A patent/BR112015002709B1/pt active IP Right Grant
- 2013-07-11 KR KR1020157006007A patent/KR102181365B1/ko active IP Right Grant
- 2013-07-11 DK DK13745491.4T patent/DK2880035T3/en active
- 2013-07-11 CA CA2881275A patent/CA2881275C/en active Active
- 2013-07-11 IN IN914DEN2015 patent/IN2015DN00914A/en unknown
- 2013-07-11 RU RU2015107831A patent/RU2645672C2/ru active
- 2013-07-11 ES ES13745491.4T patent/ES2618007T3/es active Active
- 2013-07-11 SG SG11201500872SA patent/SG11201500872SA/en unknown
- 2013-07-11 EP EP13745491.4A patent/EP2880035B9/en active Active
- 2013-07-11 EP EP16202341.0A patent/EP3170825B1/en active Active
- 2013-07-11 ES ES16202341T patent/ES2733576T3/es active Active
- 2013-07-11 MX MX2015001715A patent/MX361992B/es active IP Right Grant
- 2013-07-11 AU AU2013300106A patent/AU2013300106B2/en active Active
- 2013-07-11 LT LTEP13745491.4T patent/LT2880035T/lt unknown
- 2013-07-11 PT PT137454914T patent/PT2880035T/pt unknown
- 2013-07-11 JP JP2015526540A patent/JP6215938B2/ja active Active
- 2013-07-11 NZ NZ629807A patent/NZ629807A/en not_active IP Right Cessation
- 2013-07-11 WO PCT/US2013/050163 patent/WO2014025486A1/en active Application Filing
- 2013-07-11 CN CN201380001359.4A patent/CN103748096B/zh active Active
-
2015
- 2015-02-02 ZA ZA2015/00762A patent/ZA201500762B/en unknown
- 2015-11-16 HK HK15111282.7A patent/HK1210471A1/xx unknown
-
2016
- 2016-01-29 ZA ZA2016/00648A patent/ZA201600648B/en unknown
-
2017
- 2017-01-17 JP JP2017005935A patent/JP2017061581A/ja not_active Withdrawn
- 2017-02-23 HR HRP20170311TT patent/HRP20170311T1/hr unknown
- 2017-03-02 CY CY171100274T patent/CY1120844T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201600648B (en) | Novel pyrrolopyrimidine compounds as inhibitors of protein kinases | |
| HRP20190128T1 (hr) | Novi spojevi kao modulatori protein kinaza | |
| IL263262B (en) | Atr kinase inhibitor compounds, preparations containing them, their uses and methods for their preparation | |
| IL265007B (en) | Pyrazolopyrimidine compounds as kinase inhibitors | |
| PL2880035T3 (pl) | Nowe związki pirolopirymidynowe jako inhibitory kinaz białkowych | |
| HK1215253A1 (zh) | 作為激酶抑制劑的吡咯並嘧啶化合物 | |
| HK1215578A1 (zh) | 作為蛋白激酶抑制劑的氮雜吲哚衍生物 | |
| HK1210598A1 (en) | Di-and tri-heteroaryl derivatives as inhibitors of protein aggregation -- | |
| IL243729B (en) | Novel h4–chromin–4–one compounds as novel protein kinase modulators |